Inaugural fundraiser will feature LL Cool J, Kenny Loggins, Patricia Heaton, others.

Sherin Devaskar, UCLA

For more than 60 years, the faculty and staff at Mattel Children’s Hospital UCLA and the department of pediatrics at the David Geffen School of Medicine at UCLA have conducted pioneering research, delivered state-of-the-art patient care and expertly trained future pediatricians.

Now, under the umbrella of the recently launched UCLA Children’s Discovery and Innovation Institute, these efforts will have an even bigger and broader impact. By bringing together pediatric physician–scientists and faculty experts from a variety of fields across the UCLA campus, the new institute will drive multidisciplinary research collaborations focused on children’s health and disease and will help speed the translation of groundbreaking pediatric research findings into clinical practice — locally, nationally and globally.

“We are expanding our well-developed foundation to build a dynamic, interdisciplinary support system for our pediatric physician–scientists that fosters new avenues for innovation,” said Dr. Sherin Devaskar, physician-in-chief of Mattel Children’s Hospital UCLA and assistant vice chancellor for children’s health, who holds the Mattel Executive Endowed Chair in the UCLA Department of Pediatrics. “This new paradigm will lead to advancements that can improve the health of children faster and more efficiently.”

The institute will pioneer advancements in pediatric medicine in four key research areas: the brain and behavior; nutrition and metabolism; cancer; and inflammation, infection and immunity. Efforts in each area will focus on prevention, screening and treatment, as well as providing training opportunities for the next generation of pediatricians and mentorship programs that enable younger physicians and scientists to learn from UCLA’s cadre of experts.

Children are not “small adults,” pediatricians stress, and they experience illnesses and treatments differently than adults. The UCLA Children’s Discovery and Innovation Institute is in a unique position to collaborate with a wide variety of researchers across campus who have expertise not only in science and health but in the unique challenges young people face.

“Interdisciplinary research as envisioned by the institute is fundamental to the discoveries that pave the way to major improvements in health,” said Dr. Eugene Washington, dean of the David Geffen School of Medicine at UCLA and vice chancellor for health sciences. “Having access to a variety of specialists and experts with different points of view can be invaluable in nurturing innovations that can ultimately benefit children around the world.”

The institute will hold its inaugural fundraiser, the Kaleidoscope Ball, at the Beverly Hills Hotel on Wednesday, April 17. The sold-out event, hosted by actress Patricia Heaton, will honor philanthropists Heather and Steven Mnuchin and Cameron Cohen and musician and actor LL Cool J. Entertainment will include performances by special guests the Blue Sky Riders, Kenny Loggins, the Georgia Middleman and Gary Burr.

The event will also showcase 10 custom dollhouses created by more than 20 of the most prominent, award-winning visionaries from the world of design and architecture. The dollhouses will be auctioned off, with 100 percent of the proceeds going to support the new institute.

For more information on the UCLA Children’s Discovery and Innovation Institute, visit www.uclahealth.org/cdii.

View original article

Ultra-high resolution 7T MRI contributes to life-saving research.

Sarah Nelson, UCSF

The following was written by Sarah J. Nelson, Co-Chair of the Department of Bioengineering and Therapeutic Sciences, Director of the Center for Non-Invasive Imaging and Metabolomics and the Surbeck Laboratory of Advanced Imaging, and Margaret Hart Surbeck Distinguished Professor in the Department of Radiology and Biomedical Imaging at UC San Francisco.

The San Francisco Veterans Affairs Medical Center is currently undergoing renovations to prepare for the addition of the 7T MRI, a state of the art imaging machine that will offer researchers a more in-depth look into the details of the brain. These researchers, led by Dr. Michael Weiner, director of the Center for Imaging of Neurodegenerative Diseases (CIND) at the San Francisco VA and professor of radiology, psychiatry, and neurology at UCSF, will be able to use this new, ultra-high resolution MRI to study and analyze biological markers that play a roll in the development of dementia, Alzheimer’s disease, post-traumatic stress disorder and other cognitive diseases and issues.

Ultra-high field MR is a rapidly developing area of advanced imaging research, with only approximately 35 7T (“T” standing for tesla) MRI machines installed throughout the world. This is not the first 7T MRI for the Department of Radiology and Biomedical Imaging at UCSF, where the focus for this powerful technology has been at the Surbeck Laboratory for Advanced Imaging, in the Institute for Quantitative Biosciences on the Mission Bay campus. The 7T whole body scanner, which was installed when the building opened in 2005, has facilitated the development of a cutting edge research program for characterizing and assessing the treatment response in human diseases. New technologies for making use of this system are being developed by Drs. Duan Xu, Xiaoliang Zhang, Dan Vigneron and Peder Larson, in conjunction with GE scientist Dr. Douglas Kelley.

The results of initial studies in patients with brain tumors, multiple sclerosis and osteoarthritis have highlighted the unique forms of contrast and high sensitivity provided by the system. One of the first applications is the use of susceptibility weighted imaging to visualize the evolution of radiation induced microbleeds in the brain. Dr. Janine Lupo and her colleagues in Neurological Surgery and Radiation Oncology, are applying the methods that she has developed to assess the relationship of radiation dose with abnormal cognitive function. This has major implications for defining treatment plans that will minimize the long term side effects of radiation in children and young adults with brain cancer.

Read more

UCSF scientist Hana El-Samad receives grant for innovative cell research.

Hana El-Samad, UCLA

To explain her research into the workings of cells, UCSF scientist Hana El-Samad offers an analogy from the world of machines.

“Imagine a telephone or Internet network,” she says. “Despite their staggering complexity, packets of information find their destination on these networks and are interpreted correctly.”

Cells work in networks as well, she says, and information is constantly generated and transduced. A change in temperature of 2 degrees will change the information a cell needs to send to a gene, for instance; a change in the level of, say, glucose, will also change the information.

El-Samad is trying to understand how each change is encoded in the cells, so that it sends the right information to the genes it’s targeting, and then she wants to understand how those genes are able to decode the message.

Her novel approach in this arena won her a $1.4 million grant in February from the Paul G. Allen Family Foundation. The grants are aimed at funding high-risk but potentially high-reward research that is not typically funded by traditional sources.

Read more

Event will be May 3 in Oakland.

Mark Laret, UCSF

>>Register online or download form
>>View agenda

University of California Health colleagues are encouraged to register now for the UC Center for Health Quality and Innovation’s second spring colloquium, 9 a.m. to 4 p.m. May 3 at the Oakland Marriott City Center, 1001 Broadway, Oakland. The registration form can be downloaded or filled online.

Space is filling up for the colloquium, which is open to anyone at UC’s medical centers and health professional schools who is working to improve health care delivery, population health and efficiency of care at UC Health. Registration closes April 26.

The colloquium will address the changing health care marketplace, increasing financial challenges, and clinical and operational approaches available to UC Health to compete as health care reform unfolds.

David Lansky, Pacific Business Group on Health

UC San Francisco Medical Center CEO Mark Laret will give the keynote address, “A Call to Action for Academic Medical Centers to ‘Think Differently.’” David Lansky, president and CEO of the Pacific Business Group on Health, will provide an employer’s perspective on health care costs and quality. A panel discussion, “What Health Plans are Looking for From Providers,” will feature Paul Markovich, president and CEO of Blue Shield of California; Aldo De La Torre, vice president, provider engagement and contracting for California, Anthem Blue Cross; and Steven Sell, president of Health Net Inc.’s Western Region Health Plan and Health Net of California.

Along with remarks by UC Health Senior Vice President John Stobo, UC Chief Risk Officer Grace Crickette and innovation center Executive Director Terry Leach, there also will be poster presentations, talks from five innovation center fellows and an announcement of innovation center grant winners. (View agenda.)

The colloquium registration fee is $75. A limited number of registration fee waivers will be available for UC Health professionals, faculty and staff. Please contact claudia.schwarz@ucop.edu or (510) 987-0287 for more information.

Attendees interested in reserving a room at the Oakland Marriott City Center can take advantage of paying a group rate by April 18. Space is limited. For more information, visit the Marriott’s website or call (510) 451-4000 (reference “UCOP CHQI Colloquium” for group rate).

The colloquium has been approved for AMA PRA Category 1 Credits™ continuing medical education, jointly sponsored by the UC Davis Health System Office of Continuing Medical Education and the UC Center for Health Quality and Innovation.

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the UC Davis Health System and the UC Center for Health Quality and Innovation. The UC Davis Health System is accredited by the ACCME to provide continuing medical education for physicians.

Credit designation
Physician credit: The UC Davis Health System designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 credit acceptable for multidisciplinary team members
Nurse: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME. For the purpose of relicensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credits™ (report 4.75 hours of credit and fill in “CME Category 1” for the provider number).

Physician assistant: The National Commission on Certification of Physician Assistants (NCCPA) states that AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

About the UC Center for Health Quality and Innovation
The UC Center for Health Quality and Innovation, launched in 2010, is charged with identifying best practices, convening key stakeholders to facilitate the exchange of knowledge and funding innovative projects that demonstrate improved value in the health care delivery system. The center is governed by a board composed of the six UC medical school deans, five UC medical center CEOs and chaired by the UC Health senior vice president. For more information, visit http://health.universityofcalifornia.edu/innovation-center or email chqi.info@ucop.edu.

Dye developed at UC San Diego finds, stages cancers more accurately.

Anne Wallace, UC San Diego

Researchers at the UC San Diego School of Medicine have shown that a new imaging dye, designed and developed at UC San Diego Moores Cancer Center, is an effective agent in detecting and mapping cancers that have reached the lymph nodes. The radioactive dye called Technetium Tc-99m tilmanocept, successfully identified cancerous lymph nodes and did a better job of marking cancers than the current standard dye. Results of the phase three clinical trial published online Tuesday in the Annals of Surgical Oncology.

“Tilmanocept is a novel engineered radiopharmaceutical specifically designed for sentinel lymph node detection,” said David R. Vera, Ph.D., the drug’s inventor, who is a professor in the UCSD Department of Radiology. “The molecule, developed at UC San Diego School of Medicine, offers surgeons a new tool to accurately detect and stage melanoma and breast cancers while in the operating room.”

On March 13, tilmanocept received U.S. Food and Drug Administration approval.

After a cancer diagnosis, surgeons want to be sure that the disease has not spread to a patient’s lymph nodes, especially the sentinel nodes that may be the first place that a cancer reaches. The lymphatic system is a network of vessels and ducts that carry disease-fighting cells throughout the body, but can also act as a way for cancer cells to access the bloodstream.  By surgically removing and examining the sentinel nodes that drain a tumor, doctors can better determine if a cancer has spread.

“Tilmanocept advances the molecular targeting in breast cancer. It’s the first agent that is binding to a lymph node because it is a lymph node that plays an important role in metastasis,” said Anne Wallace, M.D., professor of surgery, UC San Diego School of Medicine and principal investigator of the study.  “Tilmanocept’s ability to identify more cancer containing nodes will lead to better post-operative care for patients, especially those patients who had more than one positive sentinel node.”

Read more

Farsighted engineer invents bionic eye to help the blind.

For UCLA bioengineering professor Wentai Liu, more than two decades of visionary research burst into the headlines last month when the FDA approved what it called “the first bionic eye for the blind.”

The Argus II Retinal Prosthesis System — developed by a team of physicians and engineers from around the country, including from Lawrence Livermore National Laboratory and UC Santa Cruz — aids adults who have lost their eyesight due to retinitis pigmentosa (RP), age-related macular degeneration or other eye diseases that destroy the retina’s light-sensitive photoreceptors.

At the heart of the device is a tiny yet powerful computer chip developed by Liu that, when implanted in the retina, effectively sidesteps the damaged photoreceptors to “trick” the eye into seeing. The Argus II operates with a miniature video camera mounted on a pair of eyeglasses that sends information about images it detects to a microprocessor worn on the user’s waistband. The microprocessor wirelessly transmits electronic signals to the computer chip, a fingernail-size grid made up of 60 circuits. These chips stimulate the retina’s nerve cells with electronic impulses which head up the optic nerve to the brain’s visual cortex. There, the brain assembles them into a composite image.

Recipients of the retinal implant can read oversized letters of the alphabet, discern objects and movement, and even see the outlines and some details of faces. And while the picture is far from perfect — the healthy human eye sees at a much higher resolution — it’s a breakthrough for people like the first patient, a man in his 70s who was blinded at age 20 by RP, to receive the implant in clinical trials. “It was the first time he’d seen light in a half-century,” said Liu, adding that “it feels good as the engineer” to have helped make this possible.

Liu joined the Artificial Retina Project in 1988 as a professor of computer and electrical engineering at North Carolina State University. The multidisciplinary research project was funded by the U.S. Department of Energy’s Office of Science because it envisioned a potential pandemic of eyesight loss in America’s aging population. Leading the project was Duke University ophthalmologist and neurosurgeon Dr. Mark Humayun, now on faculty at USC. He tapped Liu to engineer the artificial retina.

“I thought it was a great idea,” Liu said. “But I asked, ‘What can I do?’ because I didn’t know much about biology.” Humayun handed him a six-inch-thick medical manual on the retina. “The learning curve was very steep,” Liu recalled with a laugh.

However, Liu’s fellow engineers questioned his sanity. “I was working on integrated chip design and had just gotten tenure when I signed on to this project. They said, ‘You’re crazy!’ But I’m glad I made that choice, getting into this new field.”

Read more

UCSF-led project has significant potential.

Two key contributors to the UC San Francisco-led effort to create an implantable artificial kidney for dialysis patients are on Capital Hill to inform key congressional staff about the project.

Shuvo Roy, Ph.D., a bioengineer on the faculty of the UCSF School of Pharmacy and the project’s technical director, and William Fissell, M.D., an associate professor of clinical medicine at Vanderbilt University Medical Center and the project’s medical director, are in Washington, D.C., to explain the importance of the device to treat patients with end-stage renal disease (ESRD).

Affecting 2 million people worldwide, ESRD – or chronic kidney failure – is fatal unless treated and costs the nation almost $40 billion each year for treatment. And while transplantation is the most effective treatment option, donor organs are in short supply. Further, kidney dialysis is a short-term and costly treatment.

“We can provide an alternative therapy and a treatment option that doesn’t exist today for the vast majority of people today that are forced to rely on dialysis,” Roy said.

The artificial kidney project aims to combine nanoscale engineering with the most recent advances in cellular biology to create an implantable device that would enable patients with chronic kidney failure to lead healthier and more productive lives, without external dialysis or immune suppressant medication.

The kidney project is now featured in the UC Office of the President’s Onward California campaign, which aims to educate Californians about the impact the university has in their lives and to remind them of the importance of supporting the UC system.

Last year, the artificial kidney project was selected as one of the first projects to undergo more timely and collaborative review at the Food and Drug Administration. The FDA chose three renal device projects to pilot a new regulatory approval program called Innovation Pathway 2.0, intended to bring breakthrough medical device technologies to patients faster and more efficiently.

The artificial kidney project, which is targeted for clinical trials in 2017, was selected for its transformative potential in treating ESRD and for its potential to benefit from early interactions with the FDA in the approval process.

The UCSF artificial kidney, or implantable Renal Assist Device (iRAD) would include thousands of microscopic filters as well as a bioreactor to mimic the metabolic and water-balancing roles of a real kidney.

The combined treatment has been proven to work for the sickest patients using a room-sized external model developed by a team member at the University of Michigan. Roy’s goal is to apply silicon fabrication technology, along with specially engineered compartments for live kidney cells, to shrink that large-scale technology into a device the size of a coffee cup. The device would then be implanted in the body, allowing the patient to live a more normal life.

View original article

Grandfather, 57, treated at UCLA, enjoying life with his family.

Fernando Padilla could barely breathe or walk more than a few steps. An incurable disease, pulmonary fibrosis, was causing his lungs to turn to hardened scar tissue, and he was permanently tethered to an oxygen tank. His only hope was a double lung transplant.

In November 2012, he got an early-morning call that a pair of donor lungs was available.

Upon arriving at Ronald Reagan UCLA Medical Center, he was told of a new study testing an experimental device — a portable organ-preservation system that keeps donor lungs functioning and “breathing” in a near-physiologic state outside the body during transport to a recipient, instead of the standard method, in which the organs are kept in an icebox in a non-functioning, non-breathing state.

Fernando Padilla and his wife

Padilla consented to participate in the study and was randomized to become the first patient at UCLA — and in the United States — to undergo the ‘breathing lung’ transplant using the TransMedics Organ Care System (OCS).

“If they’ve got new technology to deliver the lungs still breathing, I think that would be better than trying to wake them back up again after being on ice,” said the former construction worker, who had helped build the very same hospital where he was now a patient. “I’m just following technology.”

With the OCS, the lungs are removed from a donor’s body and are placed in a mobile high-tech box, where they are immediately revived to a warm, breathing state and perfused with oxygen and a special solution supplemented with packed red-blood cells. The device also features monitors that display how the lungs are functioning during transport.

“Lungs are very sensitive and can easily be damaged during the donation process,” said Dr. Abbas Ardehali, a professor of cardiothoracic surgery and director of the heart and lung transplantation program at UCLA. “The cold-storage method does not allow for reconditioning of the lungs, but this promising technology enables us to potentially improve the function of the donor lungs before they are placed in the recipient.”

In addition, the technology could help transplant teams better assess donor lungs, since the organs can be tested in the device, over a longer period of time. It could also help address the shortage of available organs by allowing donor lungs to be safely transported across longer distances, expanding the donor pool for the more than more than 1,650 Americans who are currently on the waiting list for a lung transplant.

Padilla’s donor lungs were transported, using the OCS, from a neighboring state to UCLA. His seven-hour transplant surgery was a success, and he now relishes every deep breath. The oxygen tanks are long gone. He walks several miles a day with his wife, plays with his grandkids and enjoys life with his family. They are immensely grateful to the organ donor who supplied him with the precious “gift of life.”

Read more

Study will help physicians calculate risk of post-surgical venous thromboembolisms.

Robert Canter, UC Davis

New research from the UC Davis Comprehensive Cancer Center, published in the Journal of Surgical Research, may help clinicians determine which patients are at highest risk for post-surgical blood clots in the legs or lungs.

A team led by Robert Canter, UC Davis associate professor of surgery, studied the medical histories of more than 470,000 surgical patients to determine which factors increased their risk of blood clots, also called venous thromboembolism (VTE). The team then created a nomogram, a type of calculator, which can help clinicians predict an individual’s 30-day VTE risk. The results could change clinical practice by providing a more rational approach to preventing dangerous blood clots.

Blood clots are a critical safety and quality challenge for hospitals around the nation. While they can be prevented by administering blood thinners, such as heparin, these measures increase the risk of bleeding. To complicate matters, clinicians have had no way of determining which patients are at higher risk for blood clots, forcing them to adopt a one-size-fits-all approach to prevention.

“The standard preventive measure is heparin,” said Canter. “However, there are many questions surrounding its use: What type of heparin should be administered? What dosage? Should we give it to patients before or after surgery? By identifying patients who are at higher risk for VTE, we attempt to answer many of these questions and help to personalize treatment.”

Blood clots of the legs or lungs are a serious surgical complication, which can cause shortness of breath, longer hospital stays and, in rare cases, death. Successful treatment often requires patients to take the blood thinner Coumadin for three to six months after discharge.

The researchers combed through the American College of Surgeons National Surgical Quality Improvement (ACS-NSQIP) database to identify 471,000 patients who underwent abdominal or thoracic surgeries between 2005 and 2010. Their goal was to identify VTE events within 30 days of surgery, both in the hospital and after discharge (VTEDC). VTE includes deep vein thrombosis (clots in the legs) or pulmonary embolism (clots in the lungs).

The team considered many patient factors: age, body mass index (BMI), gender, race, pre-existing conditions, medical history, smoking and others. The group also factored in different approaches to surgery—abdominal, thoracic, laparoscopic, etc. — as well as the specific procedure type such as gastrointestinal, hernia, bariatric, splenectomy or lung. They also looked at post-operative complications, as these could affect both the length of stay and blood clot prevention efforts.

“There are a multitude of factors that go into whether a patient is at risk for VTE, as well as how to prevent it,” said Canter. “Prior to this study, no one had ever looked at so many of these factors so comprehensively.”

Read more

Related link:
Innovation Profile: Greg Maynard: Stopping blood clots, saving lives

Cutting-edge research at UC Merced explores benefits of biofilament “deformation.”

Sachin Goval (right) and UC Merced grad students

People don’t often think of deformation as a good thing.

But when it comes to biofilaments – such as strands of DNA – it’s not only good, it’s necessary for the biofilament to complete its functions. When biofilaments twist, twine, bend or loop in the ways that are correct for them, the result is a normal, healthy organism, be it a cell, an organ or a whole body.

Professor Sachin Goyal, with the UC Merced School of Engineering, and graduate student Nitish Appanasamy are modeling the “deformation” of certain biofilaments, trying to find ways to predict how such strands react when proteins, enzymes and outside forces are introduced to them.

The goal is to be able to design medications or medical treatments that will encourage biofilaments to deform in ways that cure diseases.

“In principal, it extends to any disease,” Goyal said. “It could work for injuries, too, because what’s really about is tissue damage. Every disease, every injury involves DNA.”

Goyal’s research is a perfect example of UC Merced’s cutting-edge, interdisciplinary research that could change the way medicine is practiced and applied.

Read more

Surgeon Laura Esserman to receive tribute from nationwide organization.

Laura Esserman, UC San Francisco

The American Cancer Society will pay tribute to Laura Esserman, M.D., M.B.A., an internationally known leader in the field of breast cancer care and research.

A surgeon and 20-year member of the faculty at UC San Francisco, Esserman is leading an effort to change the delivery of breast cancer services and the information systems used to support both research and patient care.

She will be honored Tuesday (March 19) at the Four Seasons Hotel in San Francisco. Established in 1913, the American Cancer Society is a nationwide voluntary health organization dedicated to eliminating cancer.

As a professor of surgery and radiology, Esserman co-leads the Breast Oncology Program and serves as associate director of the UCSF Helen Diller Family Comprehensive Cancer Center.

She is a member of President Obama’s Council of Advisors on Science and Technology (PCAST) Working Group on Advancing Innovation in Drug Development and Evaluation, which is studying how the federal government can best support science-based innovation in the process of drug development and regulatory evaluation.

Esserman has worked at UCSF to develop interdisciplinary teams of clinicians and researchers to bring the best care to patients and find the best platform to integrate translational research and improve the delivery of breast cancer care.

Director of the Carol Franc Buck Breast Care Center at UCSF, she is founder and faculty leader of the program in Translational Informatics spanning the disciplines of bioinformatics, medical and clinical informatics, systems integration, and clinical care delivery.

Esserman is the principle investigator of the I-SPY TRIAL program, a multisite neoadjuvant clinical trial that has evolved into a model for translational research and innovation in clinical trial design. I-SPY combines personalized medicine with a novel investigational design to identify women at high risk of early breast cancer recurrence. It is under way at 19 major cancer centers around the country.

Esserman has recently launched a University of California-wide breast cancer initiative called the Athena Breast Health Network, a groundbreaking project designed to follow 150,000 women from screening through treatment and outcomes, incorporating the latest in molecular testing and Web-based tools into the course of care.

Read more

Corporation for Education Network Initiatives in California honors UC Santa Cruz’s CGHub.

David Haussler, UC Santa Cruz

The UC Santa Cruz Cancer Genomics Hub (CGHub) has been honored by the Corporation for Education Network Initiatives in California (CENIC) as the recipient of the 2013 Innovations in Networking Award for High-Performance Research Applications.

UCSC has built CGHub, a 5-petabyte database, to store tumor genomes sequenced through National Cancer Institute (NCI) projects. Through this effort, CGHub is tackling the significant computational challenges posed by storing, serving, and interpreting cancer genomics data.

The CGHub mission is to facilitate the work of scientific researchers. It is designed to be a fully automated resource, appearing to the user as an extension of the user’s home institute computing system. Making such vast amounts of data accessible to collaborating researchers nationally and internationally requires advanced networking to allow the research to be carried out as seamlessly as possible.

The project is led by UC Santa Cruz bioinformatics expert David Haussler. Haussler is a distinguished professor of biomolecular engineering in the Baskin School of Engineering at UCSC and a Howard Hughes Medical Institute investigator. “By providing researchers with comprehensive catalogs of the key genomic changes in many major types and subtypes of cancer, these efforts will support the development of more effective ways to diagnose and treat cancer,” Haussler said.

Read more